Events and conference calls

Company calendar 2017

One of the main goals of the corporate communications function at MorphoSys is to inform stakeholders about the achievements and the developments within the company in an open and timely manner. Please see our full program listings for further details.

Date

Title

Add to Calendar

03/09/2017

Publication of Year-End 2016 Results
05/03/2017

Publication of First Quarter Interim Statement 2017
05/17/2017

Annual General Meeting 2017
08/03/2017

Publication of Half-Year Report 2017
11/07/2017

Publication of Third Quarter Interim Statement 2017

Upcoming
conferences

Wed

24

'17

May

UBS Global Healthcare Conference

New York, NY, USA

add date

Mon-Thu

19-22

'17

Jun

2017 BIO International Convention

San Diego, California, USA

add date

Thu

03

'17

Aug

Publication of Half-Year Report 2017

add date

Mon-Wed

06-08

'17

Nov

Bio-Europe 2017

Berlin, Germany

add date

Tue

07

'17

Nov

Publication of Third Quarter Interim Statement 2017

add date

Conferences
and webcasts

Monday, June 5, 2017 - 6:30pm
ASCO 2017

MorphoSys will present data on the Company’s proprietary programs at the American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3 - 6, 2017 in Chicago, Illionois.

MorphoSys will hold an Analyst & Investor Event on June 5, 2017 (6:30 pm CDT; June 6, 2017, 1:30 am CEST/0:30 BST) which will be broadcasted via webcast.

Go to Webcast

Presentations featured clinical data for MorphoSys’s proprietary programs MOR202 and MOR208

Abstract #7514
L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) – A single-arm phase 2 study

Abstract #8024
MOR202 with low-dose dexamethasone (DEX) and in combination with pomalidomide/DEX and lenalidomide/DEX in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase 1/2a dose-escalation study

Abstract #TPS7571
B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase 2/3 trial

Abstract #TPS7567
COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi) – A two-cohort phase 2 study

The full abstracts can be accessed online at http://abstracts.asco.org/.